Avalo Therapeutics, Inc. - Common Stock AVTX 深 沪
等待开盘 08-02 09:30:00 美东时间
7.89
0.000
0.00%
华盛通- 最 高8.7529
- 今 开7.73
- 成交量 24.21万股
- 最 低 7.5139
- 昨 收 7.89
- 总市值 632.47万
- 52周最高 16.00
- 市盈率 静 --
- 换手率 30.21%
- 52周最低 3.39
- 委 比 -99.43%
- 总股本 80.16万
- 历史最高 22032.00
- 量 比 1.20
- 振 幅 15.70%
- 历史最低 3.39
- 每 手 1
- 风险率 5.56%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多AVITA Medical to Announce Second Quarter 2025 Financial Results
AVITA Medical, Inc. announced it will report its Q2 2025 financial results after U.S. markets close on August 7, 2025. The company will host a conference call and webcast on August 8, 2025, at 6:30 a.m. Australian Eastern Standard Time (1:30 p.m. Pacific Time) to discuss its financial results and recent business highlights. The live webcast and replay will be available on the company's Investor Relations website. AVITA Medical is a leading therap...
07-28 20:05
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics, a clinical-stage biotech company focused on treating immune dysregulation, announced that its management will participate in two investor conferences: the HCW Annual Inflammation & Immunology Virtual Conference on June 30, 2025, and the BTIG Virtual Biotechnology Conference 2025 on July 29-30, 2025. The company’s lead asset, AVTX-009, is a humanized monoclonal antibody targeting IL-1β for inflammatory diseases. Webcasts and re...
06-23 11:00
Avalo Therapeutics Highlights Potential of AVTX-009 in HS
The latest announcement is out from Avalo Therapeutics ( ($AVTX) ). On June 20,...
06-20 19:28
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
Avalo Therapeutics has appointed Rita Jain, M.D., a leading rheumatologist with over two decades of experience in biopharma, to its Board of Directors. Jain's expertise in clinical development and regulatory affairs will support the advancement of AVTX-009, a Phase 2 anti-IL-1β monoclonal antibody targeting hidradenitis suppurativa (HS) and other inflammatory diseases. AVTX-009 inhibits IL-1β, a key driver of inflammation, with potential applicat...
06-18 11:00
AVITA Medical Highlights Largest Real-World Analysis Demonstrating Reduced Hospital Stay with RECELL
AVITA Medical highlights data showing reduced hospital stay for burn patients treated with its RECELL technology, supported by a study analyzing over 6,300 patients. The spray-on skin cell therapy reduces hospital stays by 6.2 days (35.7%) and saves $300 million over five years compared to traditional grafting. The study underscores RECELL’s clinical and economic benefits, with the technology used in over 130 U.S. burn centers.
06-09 13:00
AVITA Medical Announces First Clinical Publication Demonstrating Accelerated Autograft Readiness with Cohealyx™
AVITA Medical announced the first clinical publication on Cohealyx, a collagen-based dermal matrix, in the *Journal of Surgery*. The study, conducted at The Ohio State University Wexner Medical Center, showed that Cohealyx achieved autograft readiness in 5 to 10 days, significantly faster than the typical 2 to 4 weeks. Two patients with complex hand wounds saw excellent outcomes, with one ready for autografting by day 7 and the other by day 13. C...
06-05 20:04
HC Wainwright & Co. Assumes Avalo Therapeutics at Buy, Announces Price Target of $15
HC Wainwright & Co. analyst Mitchell Kapoor assumes Avalo Therapeutics (NASDAQ:AVTX) with a Buy rating and announces Price Target of $15.
06-02 18:43
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Kindly MD (NASDAQ:KDLY) stock increased by 454.4% to $21.62 during Mon...
05-12 20:09
Avalo Therapeutics Reports 2024 Financial Results
Avalo Therapeutics, Inc. ( ($AVTX) ) has released its Q4 earnings. Here is a br...
04-16 11:52
Avalo Therapeutics Appoints Michael Heffernan as Chairman
An update from Avalo Therapeutics ( ($AVTX) ) is now available. On March 25, 20...
03-26 19:27
